Navigation Links
Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics
Date:10/28/2009

On the heels of the U.S. Food & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics, Quotient Biodiagnostics, Inc., today announced that it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as its distributor to customers in the Midwest.

Newtown, PA (PRWEB) October 28, 2009 -- On the heels of the U.S. Food & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics, Quotient Biodiagnostics, Inc., today announced that it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as its distributor to customers in the Midwest.
   
MAGI, a regional specialty distributor that covers 25 percent of the U.S., will augment Quotient's direct sales force by promoting the company's products and facilitating the order process within its territory, which will create access to key customer markets throughout the Midwest. Unlike many specialty distribution organizations, MAGI is ISO 13485:2003 certified and specializes in representing companies in blood, anesthesia, vascular access, respiratory, NICU/PICU, interventional and critical care areas of the acute care hospital setting.

For customers in the rest of the country, Quotient will sell products through its direct sales force and has signed an agreement with the Global Healthcare Exchange (GHX) to provide electronic order processing in all regions outside the Midwest. As a member of GHX, Quotient is now linked with 3800 hospitals nationwide for electronic order processing and invoicing allowing greater efficiency and reduced administration costs versus typical paper processing.

"This exclusive selling agreement partners us with a highly accomplished and experienced team to bring Quotient's transfusion diagnostics products to our customers in the Midwest," said Jeremy Stackawitz, President and CEO, Quotient Biodiagnostics. "MAGI's proven success in hospital blood banks and high level of customer service is a strong match with Quotient's strategic principles. Combined with GHX, Quotient is now well positioned to service accounts nationwide."

Quotient Biodiagnostics was formed earlier this year to directly commercialize its proprietary line of products under the trade name ALBAclone®. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions at a reasonable cost.

This first BLA includes products used in forward blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-D, Anti-E, and Anti-c, as well as some rare anti-sera including Anti-k, Anti-M, Anti-N, Anti- Lea, Anti-Leb, and Anti-Lub - all monoclonal antibodies. Quotient also has two specialty products in its initial portfolio including the ALBAclone® Advanced Partial RhD Typing Kit which identifies weak and partial RhD types with result comparable to molecular analysis at a fraction of the cost, and the Quant-Rho® FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. In addition, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete a full portfolio of manual reagents of nearly 60 products.

"MED Alliance Group is excited about the opportunity to represent Quotient Biodiagnostics. We believe our specialty sales force, which has been promoting solutions to blood bank and blood center customers for over ten years, will embrace Quotient Biodiagnostics' technologies and diligently represent them to our customers," said Michael Crawford, Chief Operating Officer, MED Alliance Group, Inc.

Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visit www.quotientbd.com, or call the customer service line 888-284-1901, or e-mail customer.service(at)quotientbd.com.

About Quotient Biodiagnostics
Quotient Biodiagnostics is the diagnostics division of Quotient Bioscience Group (United Kingdom), and through its wholly owned subsidiary, Alba Bioscience, brings over 30 years experience in the transfusion medicine market to the Group. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient's goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation (initially in North America) to market and sell the Group's world leading range of blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3123734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market
2. MedAppz Signs Agreement with MedAssets to Offer SAAS-based Electronic Health Record to MedAssets' Non-acute Customers
3. Chimps Show Signs of Culture
4. Pumping Up the Volume in the Face to Reduce Signs of Aging
5. Vicon Signs License Agreement with Microsoft to Develop New Medical Technology
6. Vicon signs license agreement with Microsoft to develop new medical technology
7. Capital BlueCross Reaches Out to Former Employees of Turbine Airfoil Designs
8. Pluromed, Inc. Signs Agreement with Boston Scientific
9. SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites
10. /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
11. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has been ... still face a lot of restrictions as to where they can smoke pot. ... use” and that cannabis “may not be consumed openly or publicly.” , Given the ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent article published ... number of patients under the age of 30. According to Southern California based medical ... and may indicate an overall shift in the rapidly growing social acceptance of cosmetic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... The campaign aims to ensure 2,50,532 ... reach the milestone of their 5 th birthday   --> ... between the ages of 2 - 5 years reach the ... campaign aims to ensure 2,50,532 children ... of their 5 th birthday   India , ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
(Date:2/9/2016)... YORK, Pa., Feb. 9, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced its financial results for ... 2015). ... Revenue for the ... million in the same period last year.  Cash receipts from customers ...
Breaking Medicine Technology: